Design, synthesis, characterization, and biological evaluation of triazine dendrimers bearing paclitaxel using ester and ester/disulfide linkages

Bioconjugate Chemistry

Volumn 20, Issue 11, 2009, Pages 2154-2161

  Lim, Jongdoo ^a   Chouai, Abdellatif ^a   Lo, Su Tang ^b   Liu, Wei ^b   Sun, Xiankai ^b   Simanek, Eric E ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 PROPANEDIAMINE; 4 AMINOMETHYLPIPERIDINE; CYANURIC CHLORIDE; CYSTAMINE; DENDRIMER; ESTER; IODINE 125; MACROGOL; NITRILE; PACLITAXEL DERIVATIVE; PIPERIDINE DERIVATIVE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ACYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DISULFIDE BOND; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SYNTHESIS; ESTERIFICATION; HUMAN; HUMAN CELL; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION ANALYSIS; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

EID: 71249089119     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc900324z     Document Type: Article

References (60)

1. Haag, R., and Kratz, F. (2006) Polymer therapeutics: Concepts and applications. Angew. Chem., Int. Ed. 45, 1198-1215.
2. Esfand, R., and Tomalia, D. A. (2001) Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discovery Today 6, 427-436. (Pubitemid 32328297)
3. Duncan, R. (2003) The dawning era of polymer therapeutics. Nat. Rev. Drug Discovery 2, 347-360.
4. Putnam, D. (2008) Drug delivery: the heart of the matter. Nat. Mater. 7, 836-837.
5. Aulenta, F., Hayes, W., and Rannard, S. (2003) Dendrimers: a new class of nanoscopic containers and delivery devices. Eur. Polym. J. 39, 1741-1771.
6. Nasongkla, N., Bey, E., Ren, J., Ai, H., Khemtong, C., Guthi, J. S., Chin, S.-F., Sherry, A. D., Boothman, D. A., and Gao, J. (2006) Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett. 6, 2427-2430.
7. Lee, Y., Mo, H., Koo, H., Park, J.-Y., Cho, M. Y., Jin, G.-W., and Park, J.-S. (2007) Visualization of the degradation of a disulfide polymer, linear poly(ethylenimine sulfide), for gene delivery. Bioconjugate Chem. 18, 13-18.
8. Luten, J., Nostrum, C. F. V., Smedt, S. C. D., and Hennink, W. E. (2008) Biodegradable polymers as non-viral carriers for plasmid DNA delivery. J. Controlled Release 126, 97-110.
9. Germershaus, O., Merdan, T., Bakowsky, U., Behe, M., and Kissel, T. (2006) Trastuzumab-polyethylenimine-polyethylene glycol conjugates for targeting Her2-expressing tumors. Bioconjugate Chem. 17, 1190-1199. (Pubitemid 44455327)
10. Dautzenberg, H., Zintchenko, A., Konak, C., Reschel, T., Subr, V., and Ulbrich, K. (2001) Polycationic graft copolymers as carriers for oligonucleotide delivery. Complexes of oligonucleotides with polycationic graft copolymers. Langmuir 17, 3096-3102. (Pubitemid 35330495)
11. Wang, F., Bronich, T. K., Kabanov, A. V., Rauh, R. D., and Roovers, J. (2005) Synthesis and evaluation of a star amphiphilic block copolymer from poly(c-caprolactone) and poly(ethylene glycol) as a potential drug delivery carrier. Bioconjugate Chem. 16, 397-405. (Pubitemid 40388216)
12. Fichter, K. M., Zhang, L., Kiick, K. L., and Reineke, T. M. (2008) Peptide-functionalized poly(ethylene glycol) star polymers: DNA delivery vehicles with multivalent molecular architecture. Bioconjugate Chem. 19, 76-88. (Pubitemid 351213838)
13. Mammen, M., Choi, S. -K., and Whitesides, G. M. (1998) Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem., Int. Ed. 37, 2754-2794. (Pubitemid 29008561)
14. Fréchet, J. M. J., and Tomalia, D. A. (2001) Dendrimers and Other Dendritic Polymers, Wiley, Chichester.
15. Boas, U., and Heegaard, P. M. H. (2004) Dendrimers in drug research. Chem. Soc. Rev. 33, 43-63.
16. Cloninger, M. J. (2002) Biological applications of dendrimers. Curr. Opin. Chem. Biol. 6, 742-748.
17. Gillies, E. R., Dy, E., Fréchet, J. M. J., and Szoka, F. C. (2005) Biological evaluation of polyester dendrimer: Poly(ethylene oxide) "bow-tie" hybrids with tunable molecular weight and architecture. Mol. Pharmaceutics 2, 129-138.
18. Chen, H. T., Neerman, M. F., Parrish, A. R., and Simanek, E. E. (2004) Cytotoxicity, hemolysis, and acute in vivo toxicity of dendrimers based on melamine, candidate vehicles for drug delivery. J. Am. Chem. Soc. 126, 10044-10048.
19. Matsumura, Y., and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 6, 6387-6392. (Pubitemid 17221789)
20. Greish, K., Fang, J., Inutsuka, T., Nagamitsu, A., and Maeda, H. (2003) Macromolecular therapeutics: Advantages and prospects with special emphasis on solid tumour targeting. Clin. Pharmacokinet. 42, 1089-1105. (Pubitemid 37357647)
21. Feng, X., Taton, D., Ibarboure, E., Chaikof, E. L., and Gnanou, Y. (2008) Janus-type dendrimer-like poly(ethylene oxide)s. J. Am. Chem. Soc. 130, 11662-11676.
22. Goodwin, A. P., Lam, S. S., and Fréchet, J. M. J. (2007) Rapid, efficient synthesis of heterobifunctional biodegradable dendrimers. J. Am. Chem. Soc. 129, 6994-6995. (Pubitemid 46903254)
23. Steffensen, M. B., and Simanek, E. E. (2004) Synthesis and manipulation of orthogonally protected dendrimers: building blocks for library synthesis. Angew. Chem., Int. Ed. 43, 5178-5180.
24. Lim, J., and Simanek, E. E. (2005) Toward the next-generation drug delivery vehicle: Synthesis of a dendrimer with four orthogonally reactive groups. Mol. Pharmaceutics 2, 273-277. (Pubitemid 41186403)
25. Lim, J., Guo, Y., Rostollan, C. L., Stanfield, J., Hsieh, J. -T., Sun, X., and Simanek, E. E. (2008) The role of the size and number of polyethylene glycol chains in the biodistribution and tumor localization of triazine dendrimers. Mol. Pharmaceutics 5, 540-547.
26. Steffensen, M. B., and Simanek, E. E. (2003) Chemoselective building blocks for dendrimers from relative reactivity data. Org. Lett. 5, 2359-2361.
27. Zhang, W., Tichy, S. E., Pérez, L. M., Maria, G., Lindahl, P. A., and Simanek, E. E. (2003) Evaluation of multivalent dendrimers based on melamine: kinetics of thiol-disulfide exchange depends on the structure of the dendrimer. J. Am. Chem. Soc. 125, 5086-5094. (Pubitemid 36520438)
28. Chouai, A., and Simanek, E. E. (2008) Kilogram-scale synthesis of a second-generation dendrimer based on 1,3,5-triazine using green and industrially compatible methods with a single chromatographic step. J. Org. Chem. 73, 2357-2366.
29. Hollink, E., and Simanek, E. E. (2006) A divergent route to diversity in macromolecules. Org. Lett. 8, 2293-2295.
30. Lim, J., and Simanek, E. E. (2008) Synthesis of water-soluble dendrimers based on melamine bearing 16 paclitaxel groups. Org. Lett. 10, 201-204.
31. Patri, A. K., Kukowska-Latallo, J. F., and Baker, J. R. J. (2005) Targeted drug delivery with dendrimers: Comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv. Drug Delivery Rev. 57, 2203-2214.
32. Safavy, A., Georg, G. I., Velde, D. V., Raisch, K. P., Safavy, K., Carpenter, M., Wang, W., Bonner, J. A., Khazaeli, M. B., and Buchsbaum, D. J. (2004) Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure. Bioconjugate Chem. 15, 1264-1274. (Pubitemid 39552015)
33. Gillies, E. R., Goodwin, A. P., and Fréchet, J. M. J. (2004) Acetals as pH-sensitive linkages for drug delivery. Bioconjugate Chem. 15, 1254-1263.
34. Cui, W., Qi, M., Li, X., Huang, S., Zhou, S., and Weng, J. (2008) Electrospun fibers of acid-labile biodegradable polymers with acetal groups as potential drug carriers. Int. J. Pharm. 361, 47-55.
35. Lee, C. C., Gillies, E. R., Fox, M. E., Guillaudeu, S. J., Fréchet, J. M. J., Dy, E. E., and Szoka, F. C. (2006) A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc. Natl. Acad. Sci. U.S.A. 103, 16649-16654.
36. 6-positive cancers. Bioconjugate Chem. 19, 1813-1821.
37. El-Sayed, M. E. H., Hoffman, A. S., and Stayton, P. S. (2005) Rational design of composition and activity correlations for pH-responsive and glutathione-reactive polymer therapeutics. J. Controlled Release 104, 417-427. (Pubitemid 40724939)
38. Satchi, R., Connors, T. A., and Duncan, R. (2001) PDEPT: Polymer directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination. Br. J. Cancer 85, 1070-1076. (Pubitemid 33016011)
39. Scripture, C. D., Figg, W. D., and Sparreboom, A. (2005) Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy. Ther. Clin. Risk Manage. 1, 107-114.
40. Crown, J., O'Leary, M., and Ooi, W. S. (2004) Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 9, 24-32. (Pubitemid 38747840)
41. Singla, A. K., Garg, A., and Aggarwal, D. (2002) Paclitaxel and its formulations. Int. J. Pharm. 235, 179-192.
42. Blum, J. L., Savin, M. A., Edelman, G., Pippen, J. E., Robert, N. J., Geister, B. V., Kirby, R. L., Clawson, A., andO'Shaughnessy, J. A. (2007) Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin. Breast Cancer 7, 850-856.
43. Hawkins, M. J., Soon-Shiong, P., and Desai, N. (2008) Protein nanoparticles as drug carriers in clinical medicine. Adv. Drug Delivery Rev. 60, 876-885.
44. Bonomi, P. (2007) Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer. Expert Rev. Anticancer Ther. 7, 415-422.
45. Albain, K. S., Belani, C. P., Bonomi, P., O'Byrne, K. J., Schiller, J. H., and Socinski, M. (2006) PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2. Clin. Lung Cancer 7, 417-419. (Pubitemid 44043553)
46. Beeram, M., Rowinsky, E. K., Hammond, L. A., Patnaik, A., Schwartz, G. H., de Bono, J. S., Forero, L., Forouzesh, B., Berg, K. E., Rubin, E. H., Beers, S., Killian, A., Kwiatek, J., McGuire, J., Spivey, L., and Takimoto, C. H. (2002) A phase I pharmacokinetic (PK) study of PEG-pacltiaxel in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 21, 405.
47. Meerum Terwogt, J. M., ten Bokkel Huinink, W. W., Schellens, J. H., Schot, M., Mandjes, I. A., Zurlo, M. G., Rocchetti, M., Rosing, H., Koopman, F. J., and Beijnen, J. H. (2001) Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs 12, 315-323.
48. Khandare, J. J., Jayant, S., Singh, A., Chandna, P., Wang, Y., Vorsa, N., and Minko, T. (2006) Dendrimer versus linear conjugate: Influence of polymeric architecture on the delivery and anticancer effect of paclitaxel. Bioconjugate Chem. 17, 1464-1472. (Pubitemid 44851491)
49. Gao, Y., Chen, L., Gu, W., Xi, Y., Lin, L., and Li, Y. (2008) Targeted nanoassembly loaded with docetaxel improves intracellular drug delivery and efficacy in murine breast cancer model. Mol. Pharmaceutics 5, 1044-1054.
50. Vrudhula, V. M., MacMaster, J. F., Li, Z., Kerr, D. E., and Senter, P. D. (2002) Reductively activated disulfide prodrugs of paclitaxel. Bioorg. Med. Chem. Lett. 12, 3591-3594. (Pubitemid 35346496)
51. Majoros, I. J., Myc, A., Thomas, T., Mehta, C. B., and Baker, J. R. (2006) PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules 7, 572-579. (Pubitemid 43309153)
52. Papas, S., Akoumianaki, T., Kalogios, C., Hadjiarapolglou, L., Theodoropoulous, P. A., and Tsikaris, V. (2007) Synthesis and antitumor activity of peptide-paclitaxel conjugates. J. Pept. Sci. 13, 662-671. (Pubitemid 47570385)
53. El Alaoui, A., Saha, N., Schmidt, F., Monneret, C., and Florent, J. -C. (2006) New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy. Bioorg. Med. Chem. Lett. 14, 5012-5019. (Pubitemid 43767119)
54. Zou, Y., Fu, H., Ghosh, S., Farquhar, D., and Klostergaard, J. (2004) Antitumor activity of hydrophilic paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models. Clin. Cancer Res. 10, 7382-7391. (Pubitemid 39487728)
55. Guillemard, V., and Saragovi, H. U. (2001) Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity. Cancer Res. 61, 694-699. (Pubitemid 32140477)
56. Concentrations reported for biological assessment are referenced to the dendrimer. Correction of these values for the concentration of paclitaxel requires multiplication by 12.
57. FN: For 1, 34 nM w/o (23-50 nM 95% confidence interval); 24 nM with 1 mM GSH (17-32 nM 95% confidence interval); 30 nM with 1 mM DTT (16-58 nM 95% confidence interval). For 2, 74 nM w/o (45-121 nM 95% confidence interval); 28 nM with 1 mM GSH (21-37 nM 95% confidence interval); 16 nM with 1 mM DTT (11-24 nM 95% confidence interval). For 3, 74 nM w/o (61-90 nM 95% confidence interval); 25 nM with 1 mM GSH (17-34 nM 95% confidence interval); 11 nM with 1 mM DTT (7-20 nM 95% confidence interval). For paclitaxel, 4.5 nM (2.9-7.0 nM 95% confidence interval).
58. Fox, M. E., Guillaudeu, S., Fréchet, J. M. J., Jerger, K., Macaraeg, N., and Szoka, F. C. (2009) Synthesis and in vivo antitumor efficacy of PEGylated poly(L-lysine) dendrimer-camptothecin conjugates. Mol. Pharmaceutics, In press.
59. Deasi, N., Trieu, V., Yao, Z., Louie, L., Ci, S., Yang, A., Tao, C., De, T., Beals, B., Dykes, D., Noker, P., Yao, R., Labao, E., Hawkins, M., and Soon-Shiong, P. (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 12, 1317-1324. (Pubitemid 43342524)
60. Sparreboom, A., Scripture, C. D., Trieu, V., Williams, P. J., De, T., Yang, A., Beals, B., Figg, W. D., Hawkins, M., and Desai, N. (2005) Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophore (Taxol). Clin. Cancer Res. 11, 4136-4143. (Pubitemid 40791578)